<unk>  is delivered by injecting it directly into tumors, thereby creating a systemic anti-tumor immune response. In the US,<unk>  is FDA approved to treat Stage IIIb-IVM1c melanoma patients for whom surgical intervention is not appropriate and with tumors which can be directly injected; the EMA approved population in Europe is for Stage IIIb-IVM1a.<unk>  has been shown to extend survival in patients with Stage IIIb-IVM1a melanoma and patients who have not received prior systemic therapy for melanoma.
Talimogene laherparepvec
Ropeginterferon alfa-2b
Peginterferon alfa-2a
Peginterferon alfa-2b
Obiltoxaximab
Foscarnet
Cemiplimab
Lirentelimab